Bio-imprinted insulin-releasing biocomposites hold promise for the treatment of diabetes ”3D Printing Media Network
Fluicell, a Swedish bioprinting startup founded in 2012 as a spin-out of Chalmers University of Technology, has undertaken research to develop drugs for the treatment of type 1 diabetes. The project, which recently reached a milestone important, is based on biocomposite tissues generated by Fluicell’s Biopixlar system.
To date, there is no known cure for type 1 diabetes. Chronic autoimmune disease, which causes the immune system to break down insulin-producing beta cells in the pancreas, is mainly treated with injections. insulin. This type of therapy, while generally effective, has its own challenges, including timely administration and accessibility. In its research, Fluicell seeks to develop an alternative therapy for diabetes that uses transplantable biocomposites to effectively mimic pancreatic function by producing insulin.
The project, which is led by Fluicell’s Scientific Director, Dr Tatsiana Lobovkina, has already marked an exciting milestone with the successful bioprinting of these biocomposites. More than that, biocomposites have demonstrated the ability to release insulin based on glucose stimulation. This, as the company explains, is a key indicator of the project’s potential to eventually develop therapy for type 1 diabetes.
“We have obtained very promising results in our development of insulin-producing biocomposites which harness the strength of Biopixlar to create detailed biological tissues with programmable function and I would like to thank the entire R&D team for their excellent work”, said Dr Lobovkina. âWith Biopixlar, we can choose one or more cell types, including insulin-producing beta cells, and monitor their location and the histology of the resulting tissue. This is of crucial importance with regard to both the function and the longevity of the transplantable biocomposite. We see great potential in creating new tissue-based products for the treatment of diabetes as we move forward in development work. “
Although the research project is still in its early stages of development, the very promising results of Fluicell’s work at this point suggest that the concept of treating diabetes is sound. As such, the team will continue to advance its work towards the preclinical phase. Fluicell will also present its progress at international scientific meetings and in scientific publications.
So far, the Biopixlar bioprinter has been critical to the success of the project. Launched by Fluicell at the end of 2019, the machine combines high-resolution 2D and 3D bioprinting capabilities. Based on microfluidic technology, the bioprinter is suitable for a range of research applications, including drug development, disease understanding, and regenerative medicine research.
Notably, Fluicell has worked to advance a number of other biocomposite-based research projects with the aim of developing treatments and therapies for eye diseases (including macular degeneration) and heart failure caused by tissue damage.